ÂÞÊÏÐÂÒ»´úC5²¹ÌåÒÖÖÆ¼ÁÉÏÊÐÉêÇë±»ÄÉÈëÓÅÏÈÉóÆÀØ¡°ÃÀ¡±ÌìÐÂÒ©ÊÂ

Ò½ÏßÒ©ÎÅ
1¡¢8ÔÂ10ÈÕ£¬ÂÞÊÏçæÂÞÀûµ¥¿¹×¢ÉäÒº£¨Crovalimab£©µÄÉÏÊÐÉêÇëÒÑ»ñµÃÊÜÀí£¬²¢±»ÄÉÈëÁËÓÅÏÈÉóÆÀ¡£ÓÃÓÚÖÎÁÆÏÖÔÚδ½ÓÊܲ¹ÌåÒÖÖÆ¼ÁÖÎÁƵijÉÈ˺ÍÇàÉÙÄ꣨£¾=12Ë꣩Õó·¢ÐÔ˯ÃßÐÔѪºìÂѰ×ÄòÖ¢»¼Õß¡£ÓÐÍûʹCrovalimab³ÉΪÂÞÊÏÊ׸öÒÔÖйú×÷ΪȫÇòÊ×·¢µØµÄÁ¢ÒìÒ©Îï¡£
2¡¢8ÔÂ10ÈÕ£¬ÐÅ´ïÉúÎïÐû²¼£¬ÆäÖØ×鿹°×½éËØ23p19ÑÇ»ù¿¹Ìå×¢ÉäÒºpicankibart£¨Ñз¢´úºÅ£ºIBI112£©ÔÚÖйúÖÐÖØ¶È°ß¿éÐÍÒøÐ¼²¡ÊÜÊÔÕßÖеÄÒ»Ïî¶àÖÐÐÄ¡¢Ëæ»ú¡¢Ë«Ã¤¡¢Î¿½å¼Á±ÈÕÕµÄIIÆÚÁÙ´²Ñо¿£¨clinicaltrials.gov, NCT 05003531£©ÖеִïÖ÷ÒªÖյ㡣
3¡¢8ÔÂ9ÈÕ£¬ÖÐÒò¿Æ¼¼Ðû²¼£¬ÆäµÚ3¿îÑÛ¿Æ»ùÒò±à¼ÖÎÁƲúÆ·ZVS203e-2×¢ÉäÒº»ñÃÀ¹úFDAÊÚÓè¹Â¶ùÒ©×ʸñ£¬ÓÃÓÚÊÓÍøÄ¤É«ËØ±äÐÔµÄÖÎÁÆ¡£
4¡¢8ÔÂ9ÈÕ£¬CDE¹ÙÍøÏÔʾ£¬¸´ºêººÁصÄHLX60ÁÙ´²ÊÔÑéÉêÇë»ñÊÜÀí£¬ÓÃÓÚÖÎÁÆÊµÌåÁö¡£ÕâÊǺ£ÄÚÊ׿îÉ걨ÁÙ´²µÄGARPµ¥¿¹¡£
ͶÈÚÒ©ÊÂ
1¡¢8ÔÂ10ÈÕ£¬¿µÍþ£¨¹ãÖÝ£©ÉúÎï¿Æ¼¼ÓÐÏÞ¹«Ë¾Ðû²¼Íê³É³¬ÒÚÔªA+ÂÖÈÚ×Ê£¬ÓɹúͶ´´Òµ¶À¼ÒͶ×Ê¡£±¾ÂÖËùļ×ʽðÖ÷ÒªÓÃÓÚ¼ÓËÙÍÆ½ø¿µÍþÉúÎïÑз¢¹ÜÏßÖжà¸öÏîÄ¿µÄÁÙ´²ÊÔÑ飬ÒÔ¼°ÍƽøºóÐøÏîÄ¿µÄÁÙ´²Ç°¿ª·¢ºÍ¹ú¼ÊÏàÖú¡£
2¡¢8ÔÂ10ÈÕ£¬¾§ºËÉúÎïÒ½Ò©¿Æ¼¼£¨ÄϾ©£©ÓÐÏÞ¹«Ë¾Ðû²¼Íê³É½üÒÚÔªÈÚ×Ê¡£ÕÙļ×ʽð½«ÓÃÓÚ¼ÓËÙ¾§ºËÉúÎïÔÚÑеĶà¸öÁ¢Òì°ÐÏòºËÒ©ÍÆÏòÁÙ´²½×¶Î£¬Éý¼¶ºËËØÅ¼ÁªÒ©ÎïÑз¢Æ½Ì¨ÒÔ¼°ÍŶӽ¨Éè¡£
¿Æ¼¼Ò©ÑÐ
1¡¢¿ËÈÕ£¬Ò»Æª½ÒÏþÔÚ¹ú¼ÊÔÓÖ¾Science AdvancesÉϵÄÑо¿±¨¸æÖУ¬À´×ÔFrancis CrickÑо¿ËùµÈ»ú¹¹µÄ¿ÆÑ§¼ÒÃÇͨ¹ýÑо¿·¢Ã÷£¬½«ÃâÒßÁÆ·¨ÓëÒ»ÖÖÄÜ×è¶Ï·Î°©Öг£¼û»ùÒòÍ»±äµÄÒ©ÎKRASÒÖÖÆ¼Á£©Á¬ÏµÔÚÒ»Æð»òÐíÄÜ×÷ΪһÖÖÖÎÁÆÌض¨·Î²¿Ö×ÁöµÄÐÂÐÍ×éºÏÐÔÁÆ·¨£¬Ïà¹ØÑо¿Ð§¹û»òÄÜ×ÊÖúÑо¿Ö°Ô±Ñ¡Ôñ»¼Õß¾ÙÐÐÁÙ´²ÊÔÑ飬´Ó¶øÖ¤ÊµÕâÖÖ×éºÏÐÔÁÆ·¨ÊÇ·ñÄܶÔÈËÀàÓÐÓÃ[1]¡£
[1] EDURNE MUGARZA£¬FEBE VAN MALDEGEM£¬XJESSE BOUMELHA, et al. Therapeutic KRASG12C inhibition drives effective interferon-mediated anti-tumour immunity in immunogenic lung cancers, Science Advances (2022). DOI: 10.1126/sciadv.abm8780
